Potential of circulating lncRNA CASC2 as a biomarker in reflecting the inflammatory cytokines, multi-organ dysfunction, disease severity, and mortality in sepsis patients.
inflammation
lncRNA CASC2
mortality
organ injury
sepsis
Journal
Journal of clinical laboratory analysis
ISSN: 1098-2825
Titre abrégé: J Clin Lab Anal
Pays: United States
ID NLM: 8801384
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
revised:
06
06
2022
received:
10
05
2022
accepted:
11
06
2022
pubmed:
28
6
2022
medline:
25
8
2022
entrez:
27
6
2022
Statut:
ppublish
Résumé
Long noncoding RNA (lncRNA) cancer susceptibility candidate gene 2 (CASC2) inhibits inflammation and multi-organ dysfunction in various ways. The present study was intended to explore the potency of blood lncRNA CASC2 as a biomarker for sepsis management. Totally, 184 sepsis patients and 30 healthy controls were enrolled. The reverse transcription-quantitative polymerase chain reaction was used to detect lncRNA CASC2 expression in peripheral blood mononuclear cell samples from the subjects. Mortality during 28 days was recorded in sepsis patients. LncRNA CASC2 was decreased in sepsis patients [median (interquartile range [IQR]): 0.473 (0.241-0.773)] by comparison to healthy controls [median (IQR): 1.019 (0.676-1.685)] (p < 0.001). In sepsis patients, lncRNA CASC2 was negatively correlated with Acute Physiology and Chronic Health Evaluation II (APACHE II) (p = 0.001), Sequential Organ Failure Assessment (SOFA) (p < 0.001), SOFA-respiratory system (p = 0.010), SOFA-coagulation (p = 0.020), SOFA-liver (p = 0.019), and SOFA-renal (p = 0.010) scores, but was not related to SOFA-nervous (p = 0.466) and SOFA-cardio vascular system (p = 0.059) scores. Additionally, lncRNA CASC2 was negatively related to tumor necrosis factor-α (p = 0.024), interleukin (IL)-1β (p = 0.013), and IL-17A (p = 0.002), but was not linked to IL-6 (p = 0.112) or IL-10 (p = 0.074). Furthermore, lncRNA CASC2 was lower in sepsis deaths [median (IQR): 0.286 (0.166-0.475)] than in survivors [median (IQR): 0.534 (0.296-0.811)] (p < 0.001). Simultaneously, Kaplan-Meier (KM) curve analysis also observed that lncRNA CASC2 was inversely related to accumulating mortality in sepsis patients (p = 0.003). While lncRNA CASC2 could independently predict lower mortality risk. Circulating lncRNA CASC2 inadequacy indicates the release of inflammatory cytokines, severe multi-organ injuries, and increased mortality in sepsis patients.
Sections du résumé
BACKGROUND
BACKGROUND
Long noncoding RNA (lncRNA) cancer susceptibility candidate gene 2 (CASC2) inhibits inflammation and multi-organ dysfunction in various ways. The present study was intended to explore the potency of blood lncRNA CASC2 as a biomarker for sepsis management.
METHODS
METHODS
Totally, 184 sepsis patients and 30 healthy controls were enrolled. The reverse transcription-quantitative polymerase chain reaction was used to detect lncRNA CASC2 expression in peripheral blood mononuclear cell samples from the subjects. Mortality during 28 days was recorded in sepsis patients.
RESULTS
RESULTS
LncRNA CASC2 was decreased in sepsis patients [median (interquartile range [IQR]): 0.473 (0.241-0.773)] by comparison to healthy controls [median (IQR): 1.019 (0.676-1.685)] (p < 0.001). In sepsis patients, lncRNA CASC2 was negatively correlated with Acute Physiology and Chronic Health Evaluation II (APACHE II) (p = 0.001), Sequential Organ Failure Assessment (SOFA) (p < 0.001), SOFA-respiratory system (p = 0.010), SOFA-coagulation (p = 0.020), SOFA-liver (p = 0.019), and SOFA-renal (p = 0.010) scores, but was not related to SOFA-nervous (p = 0.466) and SOFA-cardio vascular system (p = 0.059) scores. Additionally, lncRNA CASC2 was negatively related to tumor necrosis factor-α (p = 0.024), interleukin (IL)-1β (p = 0.013), and IL-17A (p = 0.002), but was not linked to IL-6 (p = 0.112) or IL-10 (p = 0.074). Furthermore, lncRNA CASC2 was lower in sepsis deaths [median (IQR): 0.286 (0.166-0.475)] than in survivors [median (IQR): 0.534 (0.296-0.811)] (p < 0.001). Simultaneously, Kaplan-Meier (KM) curve analysis also observed that lncRNA CASC2 was inversely related to accumulating mortality in sepsis patients (p = 0.003). While lncRNA CASC2 could independently predict lower mortality risk.
CONCLUSION
CONCLUSIONS
Circulating lncRNA CASC2 inadequacy indicates the release of inflammatory cytokines, severe multi-organ injuries, and increased mortality in sepsis patients.
Identifiants
pubmed: 35754113
doi: 10.1002/jcla.24569
pmc: PMC9396177
doi:
Substances chimiques
Biomarkers
0
Cytokines
0
RNA, Long Noncoding
0
Tumor Suppressor Proteins
0
long non-coding RNA CASC2, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e24569Subventions
Organisme : Protective Effects of oxymatrine on sepsis in rats
ID : No. 204106107
Informations de copyright
© 2022 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.
Références
Immunity. 2021 Nov 9;54(11):2450-2464
pubmed: 34758337
JAMA Netw Open. 2019 Feb 1;2(2):e187571
pubmed: 30768188
Bioengineered. 2022 Feb;13(2):3240-3250
pubmed: 35045800
Int J Mol Med. 2020 May;45(5):1554-1562
pubmed: 32323747
J Clin Lab Anal. 2022 Aug;36(8):e24569
pubmed: 35754113
Eur Rev Med Pharmacol Sci. 2020 Aug;24(16):8367-8376
pubmed: 32894543
Mol Med Rep. 2020 Dec;22(6):5181-5190
pubmed: 33174006
Yale J Biol Med. 2019 Dec 20;92(4):629-640
pubmed: 31866778
Int J Biol Sci. 2020 May 18;16(12):2116-2130
pubmed: 32549759
J Surg Res. 2021 Sep;265:223-232
pubmed: 33957574
Ther Adv Respir Dis. 2021 Jan-Dec;15:17534666211028072
pubmed: 34266334
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Exp Cell Res. 2021 Sep 15;406(2):112756
pubmed: 34384779
Kidney Blood Press Res. 2020;45(6):837-849
pubmed: 33227790
Int J Hematol. 2021 Jan;113(1):24-33
pubmed: 33386597
Med Sci Monit. 2021 Sep 10;27:e932227
pubmed: 34504051
Crit Care Med. 2020 Mar;48(3):e209-e218
pubmed: 31804299
Hum Mutat. 2004 Apr;23(4):318-26
pubmed: 15024726
Cell Biosci. 2018 Feb 26;8:15
pubmed: 29492259
Lancet. 2020 Jan 18;395(10219):200-211
pubmed: 31954465
Immunol Invest. 2022 Jul;51(5):1257-1271
pubmed: 34165388
Crit Care. 2020 Oct 19;24(1):614
pubmed: 33076940